FEDAA-1106
Multiple Sclerosis
BayerSmall moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 65/ 100
Competitive context
183 Active assets in the Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cladribine University Hospital, Strasbourg, France | Phase 4 | BBB |
Nabiximols Jazz Pharmaceuticals | Phase 4 | BBB |
Teriflunomide Sanofi | Phase 4 | BBB |
Fampridine MGH Institute of Health Professions | Phase 4 | BBB |
Ocrevus Polpharma Biologics International AG | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
FEDAA-1106 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →